Tachykinin receptor | |
---|---|
Identifiers | |
Symbol | ? |
InterPro | IPR001681 |
tachykinin receptor 1 | |||||||
---|---|---|---|---|---|---|---|
Identifiers | |||||||
Symbol | TACR1 | ||||||
Alt. symbols | TAC1R | ||||||
NCBI gene | 6869 | ||||||
HGNC | 11526 | ||||||
OMIM | 162323 | ||||||
RefSeq | NM_001058 | ||||||
UniProt | P25103 | ||||||
Other data | |||||||
Locus | Chr. 2 p13.1-p12 | ||||||
|
tachykinin receptor 2 | |||||||
---|---|---|---|---|---|---|---|
Identifiers | |||||||
Symbol | TACR2 | ||||||
Alt. symbols | TAC2R, NKNAR | ||||||
NCBI gene | 6865 | ||||||
HGNC | 11527 | ||||||
OMIM | 162321 | ||||||
RefSeq | NM_001057 | ||||||
UniProt | P21452 | ||||||
Other data | |||||||
Locus | Chr. 10 q11-q21 | ||||||
|
tachykinin receptor 3 | |||||||
---|---|---|---|---|---|---|---|
Identifiers | |||||||
Symbol | TACR3 | ||||||
NCBI gene | 6870 | ||||||
HGNC | 11528 | ||||||
OMIM | 162332 | ||||||
RefSeq | NM_001059 | ||||||
UniProt | P29371 | ||||||
Other data | |||||||
Locus | Chr. 4 q25 | ||||||
|
There are three known mammalian tachykinin receptors termed NK1, NK2 and NK3. All are members of the 7 transmembrane G-protein coupled receptor family and induce the activation of phospholipase C, producing inositol triphosphate (so called Gq-coupled).
Inhibitors of NK-1, known as NK-1 receptor antagonists, can be used as antiemetic agents, such as the drug aprepitant. [1]
The genes and receptor ligands are as follows: [2]
Receptor | Gene | Preferred ligand |
NK1 | TACR1 | substance P |
NK2 | TACR2 | neurokinin A |
NK3 | TACR3 | neurokinin B |
(Hökfelt et al., 2001; Page, 2004; Pennefather et al., 2004; Maggi, 2000)
Substance P (SP) is an undecapeptide member of the tachykinin neuropeptide family. It is a neuropeptide, acting as a neurotransmitter and as a neuromodulator. Substance P and its closely related neurokinin A (NKA) are produced from a polyprotein precursor after differential splicing of the preprotachykinin A gene. The deduced amino acid sequence of substance P is as follows:
Aprepitant, sold under the brand name Emend among others, is a medication used to prevent chemotherapy-induced nausea and vomiting (CINV) and to prevent postoperative nausea and vomiting. It may be used together with ondansetron and dexamethasone. It is taken by mouth.
Tachykinin peptides are one of the largest families of neuropeptides, found from amphibians to mammals. They were so named due to their ability to rapidly induce contraction of gut tissue. The tachykinin family is characterized by a common C-terminal sequence, Phe-X-Gly-Leu-Met-NH2, where X is either an Aromatic or an Aliphatic amino acid. The genes that produce tachykinins encode precursor proteins called preprotachykinins, which are chopped apart into smaller peptides by posttranslational proteolytic processing. The genes also code for multiple splice forms that are made up of different sets of peptides.
Neurokinin 1 (NK1) antagonists (-pitants) are a novel class of medications that possesses unique antidepressant, anxiolytic, and antiemetic properties. NK-1 antagonists boost the efficacy of 5-HT3 antagonists to prevent nausea and vomiting. The discovery of neurokinin 1 (NK1) receptor antagonists was a turning point in the prevention of nausea and vomiting associated with cancer chemotherapy.
Neurokinin A (NKA), formerly known as Substance K, is a neurologically active peptide translated from the pre-protachykinin gene. Neurokinin A has many excitatory effects on mammalian nervous systems and is also influential on the mammalian inflammatory and pain responses.
The tachykinin receptor 1 (TACR1) also known as neurokinin 1 receptor (NK1R) or substance P receptor (SPR) is a G protein coupled receptor found in the central nervous system and peripheral nervous system. The endogenous ligand for this receptor is Substance P, although it has some affinity for other tachykinins. The protein is the product of the TACR1 gene.
G protein-coupled receptor 6, also known as GPR6, is a protein which in humans is encoded by the GPR6 gene.
Substance-K receptor is a protein that in humans is encoded by the TACR2 gene.
Tachykinin receptor 3, also known as TACR3, is a protein which in humans is encoded by the TACR3 gene.
Relaxin/insulin-like family peptide receptor 3, also known as RXFP3, is a human G-protein coupled receptor.
G-protein coupled receptor 161 is a protein that in humans is encoded by the GPR161 gene.
Neuromedin-U receptor 1 is a protein that in humans is encoded by the NMUR1 gene.
Neuromedin-U receptor 2 is a protein that in humans is encoded by the NMUR2 gene.
Tachykinin-3 is a protein that in humans is encoded by the TAC3 gene.
Tachykinin-4 is a protein that in humans is encoded by the TAC4 gene.
Osanetant (SR-142,801) was a neurokinin 3 receptor antagonist developed by Sanofi-Synthélabo, which was being researched for the treatment of schizophrenia, but was discontinued. It was the first non-peptide NK3 antagonist developed in the mid-1990s, Other potential applications for osanetant is in the treatment of drug addiction, as it has been found to block the effects of cocaine in animal models.
GR-159897 is a potent and selective NK2 receptor antagonist drug. It has anxiolytic effects in animal models, and also inhibits bronchoconstriction of the airways, which may potentially make it useful in the treatment of asthma.
L-733,060 is a drug developed by Merck which acts as an orally active, non-peptide, selective antagonist for the NK1 receptor, binding with a Ki of 0.08 nM. Only one enantiomer is active which has made it the subject of several asymmetric synthesis efforts.
Ezlopitant (INN, code name CJ-11,974) is an NK1 receptor antagonist. It has antiemetic and antinociceptive effects. Pfizer was developing ezlopitant for the treatment of irritable bowel syndrome but it appears to have been discontinued.
Netupitant is an antiemetic drug. In the United States, the combination drug netupitant/palonosetron is approved by the Food and Drug Administration for prevention of acute and delayed chemotherapy-induced nausea and vomiting, including highly emetogenic chemotherapy such as with cisplatin. In Europe, it is approved by the European Medicines Agency (EMA) for the same indication.
This biochemistry article is a stub. You can help Wikipedia by expanding it. |